The product license of buprenorphine/naloxone for opioid substitution therapy indicates reducing methadone concentrations to 30 mg or less per day for a minimum of 1 week before transferring patients to buprenorphine and no sooner than 24 hours after the last methadone dose, because of the risk of precipitated withdrawal and a corresponding high risk of relapse to opioid use. There are few studies describing high-dose methadone transfers. This retrospective case review assessed the feasibility of transferring patients on methadone doses above 30 mg/day to buprenorphine or buprenorphine/naloxone in the inpatient setting. (Source: Journal of Substance Abuse Treatment)

The product license of buprenorphine/naloxone for opioid substitution therapy indicates reducing methadone concentrations to 30 mg or less per day for a minimum of 1 week before transferring patients to buprenorphine and no sooner than 24 hours after the last methadone dose, because of the risk of precipitated withdrawal and a corresponding high risk of relapse to opioid use. There are few studies describing high-dose methadone transfers. This retrospective case review assessed the feasibility of transferring patients on methadone doses above 30 mg/day to buprenorphine or buprenorphine/naloxone in the inpatient setting. (Source: Journal of Substance Abuse Treatment)

CONCLUSIONS: A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to investigate real-world acceptability of XR-NTX as an additional option for the treatment of opioid use disorder.
PMID: 25935714 [PubMed – as supplied by publisher] (Source: Addiction Science and Clinical Practice)

CONCLUSIONS: A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to investigate real-world acceptability of XR-NTX as an additional option for the treatment of opioid use disorder.
PMID: 25935714 [PubMed – as supplied by publisher] (Source: Addiction Science and Clinical Practice)

Conclusions:
A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to investigate real-world acceptability of XR-NTX as an additional option for the treatment of opioid use disorder. (Source: Epidemiologic Perspectives and Innovations)

Conclusions:
A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to investigate real-world acceptability of XR-NTX as an additional option for the treatment of opioid use disorder. (Source: Epidemiologic Perspectives and Innovations)

ConclusionsThe introduction of BNX film in Australia varied across States. A perception of restricted choice in medication may have undermined initial acceptance in SA. [Larance B, Dietze P, Ali R, Lintzeris N, White N, Jenkinson R, Degenhardt L. The introduction of BNX film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations. Drug Alcohol Rev 2015;●●:●●–●●] (Source: Drug and Alcohol Review)

The objective of this study was to compare resource utilisation and associated healthcare costs between the OPD patients treated with buprenorphine/naloxone combination and OPD patients without pharmacological treatment from the German healthcare perspective. (Source: Value in Health)

By Daniel J. Pallin, MD, MPH Opioid-dependent individuals visiting the emergency department are much more likely to participate in addiction treatment when buprenorphine/naloxone therapy is started during the visit, a JAMA study finds.Investigators randomized some 330 adult patients reporting opioid dependence to one of … (Source: Physician’s First Watch current issue)

By Daniel J. Pallin, MD, MPH Opioid-dependent individuals visiting the emergency department are much more likely to participate in addiction treatment when buprenorphine/naloxone therapy is started during the visit, a JAMA study finds.Investigators randomized some 330 adult patients reporting opioid dependence to one of … (Source: Physician’s First Watch current issue)